Will Madrigal Pharmaceuticals Incorporated (NASDAQ:MDGL) Run Out of Steam Soon? Short Interest Is Down

February 15, 2018 - By marketbeat

 Will Madrigal Pharmaceuticals Incorporated (NASDAQ:MDGL) Run Out of Steam Soon? Short Interest Is Down

The stock of Madrigal Pharmaceuticals Incorporated (NASDAQ:MDGL) registered a decrease of 5.2% in short interest. MDGL’s total short interest was 269,700 shares in February as published by FINRA. Its down 5.2% from 284,500 shares, reported previously. With 66,400 shares average volume, it will take short sellers 4 days to cover their MDGL’s short positions. The short interest to Madrigal Pharmaceuticals Incorporated’s float is 5.64%.

The stock increased 0.79% or $1.03 during the last trading session, reaching $131.15. About 133,580 shares traded. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company has market cap of $1.84 billion. The company’s lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It currently has negative earnings. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials.

More notable recent Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) news were published by: Seekingalpha.com which released: “Madrigal Pharmaceuticals: Buy The Secondary” on December 20, 2017, also Seekingalpha.com with their article: “Madrigal Continues Its Success With Another High Target Indication” published on February 09, 2018, Fool.com published: “Why Madrigal Pharmaceuticals Stock Is On Fire Today” on December 06, 2017. More interesting news about Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) were released by: Seekingalpha.com and their article: “Madrigal Pharmaceuticals: Elucidating The Positive Outcomes Of The Phase 2 …” published on February 11, 2018 as well as Fool.com‘s news article titled: “Why Aquantia, Thomson Reuters, and Madrigal Pharmaceuticals Jumped Today” with publication date: January 30, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: